Menu Search
Equities

Diamyd Medical AB

DMN:FRA

Diamyd Medical AB

Actions
  • Price (EUR)1.17
  • Today's Change0.000 / 0.00%
  • Shares traded7.00k
  • 1 Year change+80.83%
  • Beta--
Data delayed at least 15 minutes, as of Sep 23 2024 10:34 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Diamyd Medical AB's net income fell 12.13% from a loss of 103.52m to a larger loss of 116.07m despite revenues that grew 20.26% from 454.00k to 546.00k. An increase in the selling, general and administrative costs as a percentage of sales from 4,462.33% to 4,699.27% was a component in the falling net income despite rising revenues.
Gross margin-7,386.02%
Net profit margin-75,065.59%
Operating margin-76,889.78%
Return on assets-68.99%
Return on equity-84.24%
Return on investment-76.65%
More ▼

Cash flow in SEKView more

In 2023, Diamyd Medical AB increased its cash reserves by 6.49%, or 7.77m. Cash Flow from Financing totalled 86.54m or 15,850.18% of revenues. In addition the company used 110.96m for operations while cash from investing totalled 28.40m.
Cash flow per share-1.49
Price/Cash flow per share--
Book value per share1.96
Tangible book value per share1.96
More ▼

Balance sheet in SEKView more

Diamyd Medical AB appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 127.53m.
Current ratio8.87
Quick ratio--
Total debt/total equity0.1615
Total debt/total capital0.1391
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.